STEPHEN L. SABBA, M.D. - Corporate Board Profile

LIGAND PHARMACEUTICALS INC

Filing Date	Source Excerpt
2018-04-30	Stephen L. Sabba, M.D. Director 2008 58; Member of the audit and nominating and corporate governance committees; 2017 compensation total $281,078.
2019-04-24	Stephen L. Sabba, M.D. (A)(N) 59 2008 Leading Bio/Pharma Analyst and Fund Manager for Knott Partners, L.P ... Dr. Sabba received 493 restricted stock units with a grant date fair value of $96,584 and 2,474 stock options with a grant date fair value of $186,596. Total: $353,365.
2020-04-24	Stephen L. Sabba, M.D. (A)(N) 60 2008 Leading Health Care Analyst and Portfolio Manager for Knott Partners, L.P ... Dr. Sabba’s experience in accounting and capital markets and deep knowledge of the biopharmaceutical industry, including his background as a medical doctor, contributed to our board of directors’ conclusion that he should serve as a director of our company. ... The audit committee currently consists of Dr. Gray, Mr. Patel and Dr. Sabba (chair). ... Stephen L. Sabba 75,027 94,848 190,025 359,900 ... (6) As of December 31, 2019, Dr. Sabba held options to purchase 39,401 shares of our common stock and 835 restricted stock units. During 2019, Dr. Sabba received 835 restricted stock units with a grant date fair value of $94,848 and 4,071 stock options with a grant date fair value of $190,025.
2021-04-23	Stephen L. Sabba, M.D., has served as a member of our board of directors since August 2008. Dr. Sabba has been a leading Bio/Pharma Analyst and Fund Manager for Knott Partners, L.P., an investment fund company, since November 2006. Previously he was a Partner and Director of Research with Kilkenny Capital Management, a Chicago-based Health Care hedge fund. Prior to that, Dr. Sabba was Director of Research at Sturza’s Medical Research, and previously was a gastroenterologist and internist in private practice at Phelps Hospital in North Tarrytown, New York. He received his M.D. from the New York University School of Medicine, and completed a residency in internal medicine and a fellowship in gastroenterology at the Veterans Administration Medical Center in New York City. He earned a B.S. with honors at Cornell University. Dr. Sabba served as a member of the board of the directors for Novelion Therapeutics Inc., a leading Canadian biotech company from June 2012 to January 2020. Dr. Sabba’s experience in accounting and capital markets and deep knowledge of the biopharmaceutical industry, including his background as a medical doctor, contributed to our board of directors’ conclusion that he should serve as a director of our company.
2022-04-22	Stephen L. Sabba, M.D., has served as a member of our board of directors since August 2008. Dr. Sabba is a leading Bio/Pharma Analyst and Portfolio Manager for Knott Partners, L.P. He is a member of the audit committee. Total compensation for 2021 was $332,807.
2023-04-20	Stephen L. Sabba, M.D., has served as a member of the Board since August 2008. Dr. Sabba has been a leading BioPharma Analyst and Fund Manager for Knott Partners, L.P., an investment fund company, since November 2006. Previously he was a Partner and Director of Research with Kilkenny Capital Management, a Chicago-based healthcare hedge fund. Prior to that, Dr. Sabba was Director of Research at Sturza’s Medical Research, and previously was a gastroenterologist and internist in private practice at Phelps Hospital in North Tarrytown, New York. He received his M.D. from the New York University School of Medicine, and completed a residency in internal medicine and a fellowship in gastroenterology at the Veterans Administration Medical Center in New York City. He earned a B.S. with honors at Cornell University. Dr. Sabba served as a member of the board of the directors for Novelion Therapeutics Inc., a leading Canadian biotech company from June 2012 to January 2020. Dr. Sabba’s experience in accounting and capital markets and deep knowledge of the biopharmaceutical industry, including his background as a medical doctor, contributed to the Board’ conclusion that he should serve as a director of our company.
2024-04-25	Stephen L. Sabba, M.D. (A) 64 2008 Leading BioPharma Analyst and Fund Manager for Knott Partners, L.P. ... (A) Member of the audit committee (the “Audit Committee”). (HC) Member of the human capital management and compensation committee (the “Human Capital Management and Compensation Committee”). (N) Member of the nominating and corporate governance committee (the “Nominating and Corporate Governance Committee”). ... DIRECTOR COMPENSATION TABLE ... Stephen L. Sabba, M.D. 70,096 84,234 187,371 341,701 ... The Audit Committee currently consists of Dr. Gray, Mr. Haas and Dr. Sabba (Chair).